1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Guillain-Barre Syndrome Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Guillain-Barre Syndrome Market Analysis and Forecast, 2017–2031
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global Guillain-Barre Syndrome Market Analysis and Forecast, by Therapeutics
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Therapeutics, 2017–2031
6.3.1. Intravenous Immunoglobulin
6.3.2. Plasma Exchange
6.3.3. Others
6.4. Market Attractiveness Analysis, by Therapeutics
7. Global Guillain-Barre Syndrome Market Analysis and Forecast, by Route of Administration
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Route of Administration, 2017–2031
7.3.1. Oral
7.3.2. Parenteral
7.4. Market Attractiveness Analysis, by Route of Administration
8. Global Guillain-Barre Syndrome Market Analysis and Forecast, by Distribution Channel
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Distribution Channel, 2017–2031
8.3.1. Hospitals
8.3.2. Pharmacies
8.3.3. Retail Pharmacies
8.3.4. Others
8.4. Market Attractiveness Analysis, by Distribution Channel
9. Global Guillain-Barre Syndrome Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region, 2017–2031
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. South America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region
10. North America Guillain-Barre Syndrome Market Analysis and Forecast
10.1. Introduction
10.2. Key Findings
10.3. Market Value Forecast, by Therapeutics, 2017–2031
10.3.1. Intravenous Immunoglobulin
10.3.2. Plasma Exchange
10.3.3. Others
10.4. Market Value Forecast, by Route of Administration, 2017–2031
10.4.1. Oral
10.4.2. Parenteral
10.5. Market Value Forecast, by Distribution Channel, 2017–2031
10.5.1. Hospitals
10.5.2. Pharmacies
10.5.3. Retail Pharmacies
10.5.4. Others
10.6. Market Value Forecast, by Country, 2017–2031
10.6.1. U.S.
10.6.2. Canada
10.7. Market Attractiveness Analysis
10.7.1. By Therapeutics
10.7.2. By Route of Administration
10.7.3. By Distribution Channel
10.7.4. By Country
11. Europe Guillain-Barre Syndrome Market Analysis and Forecast
11.1. Introduction
11.2. Key Findings
11.3. Market Value Forecast, by Therapeutics, 2017–2031
11.3.1. Intravenous Immunoglobulin
11.3.2. Plasma Exchange
11.3.3. Others
11.4. Market Value Forecast, by Route of Administration, 2017–2031
11.4.1. Oral
11.4.2. Parenteral
11.5. Market Value Forecast, by Distribution Channel, 2017–2031
11.5.1. Hospitals
11.5.2. Pharmacies
11.5.3. Retail Pharmacies
11.5.4. Others
11.6. Market Value Forecast, by Country/Sub-region, 2017–2031
11.6.1. Germany
11.6.2. U.K.
11.6.3. France
11.6.4. Italy
11.6.5. Spain
11.6.6. Rest of Europe
11.7. Market Attractiveness Analysis
11.7.1. By Therapeutics
11.7.2. By Route of Administration
11.7.3. By Distribution Channel
11.7.4. By Country/Sub-region
12. Asia Pacific Guillain-Barre Syndrome Market Analysis and Forecast
12.1. Introduction
12.2. Key Findings
12.3. Market Value Forecast, by Therapeutics, 2017–2031
12.3.1. Intravenous Immunoglobulin
12.3.2. Plasma Exchange
12.3.3. Others
12.4. Market Value Forecast, by Route of Administration, 2017–2031
12.4.1. Oral
12.4.2. Parenteral
12.5. Market Value Forecast, by Distribution Channel, 2017–2031
12.5.1. Hospitals
12.5.2. Pharmacies
12.5.3. Retail Pharmacies
12.5.4. Others
12.6. Market Value Forecast, by Country/Sub-region, 2017–2031
12.6.1. China
12.6.2. Japan
12.6.3. India
12.6.4. Australia & New Zealand
12.6.5. Rest of Asia Pacific
12.7. Market Attractiveness Analysis
12.7.1. By Therapeutics
12.7.2. By Route of Administration
12.7.3. By Distribution Channel
12.7.4. By Country/Sub-region
13. South America Guillain-Barre Syndrome Market Analysis and Forecast
13.1. Introduction
13.2. Key Findings
13.3. Market Value Forecast, by Therapeutics, 2017–2031
13.3.1. Intravenous Immunoglobulin
13.3.2. Plasma Exchange
13.3.3. Others
13.4. Market Value Forecast, by Route of Administration, 2017–2031
13.4.1. Oral
13.4.2. Parenteral
13.5. Market Value Forecast, by Distribution Channel, 2017–2031
13.5.1. Hospitals
13.5.2. Pharmacies
13.5.3. Retail Pharmacies
13.5.4. Others
13.6. Market Value Forecast, by Country/Sub-region, 2017–2031
13.6.1. Brazil
13.6.2. Mexico
13.6.3. Rest of South America
13.7. Market Attractiveness Analysis
13.7.1. By Therapeutics
13.7.2. By Route of Administration
13.7.3. By Distribution Channel
13.7.4. By Country/Sub-region
14. Middle East & Africa Guillain-Barre Syndrome Market Analysis and Forecast
14.1. Introduction
14.2. Key Findings
14.3. Market Value Forecast, by Therapeutics, 2017–2031
14.3.1. Intravenous Immunoglobulin
14.3.2. Plasma Exchange
14.3.3. Others
14.4. Market Value Forecast, by Route of Administration, 2017–2031
14.4.1. Oral
14.4.2. Parenteral
14.5. Market Value Forecast, by Distribution Channel, 2017–2031
14.5.1. Hospitals
14.5.2. Pharmacies
14.5.3. Retail Pharmacies
14.5.4. Others
14.6. Market Value Forecast, by Country/Sub-region, 2017–2031
14.6.1. GCC Countries
14.6.2. South Africa
14.6.3. Rest of Middle East & Africa
14.7. Market Attractiveness Analysis
14.7.1. By Therapeutics
14.7.2. By Route of Administration
14.7.3. By Distribution Channel
14.7.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player – Competitive Matrix (by Tier and Size of Companies)
15.2. Market Share Analysis, by Company (2022)
15.3. Company Profiles
15.3.1. Grifols S.A
15.3.1.1. Company Overview
15.3.1.2. Product Portfolio
15.3.1.3. SWOT Analysis
15.3.1.4. Financial Overview
15.3.1.5. Strategic Overview
15.3.2. CSL Behring LLC
15.3.2.1. Company Overview
15.3.2.2. Product Portfolio
15.3.2.3. SWOT Analysis
15.3.2.4. Financial Overview
15.3.2.5. Strategic Overview
15.3.3. Shire plc
15.3.3.1. Company Overview
15.3.3.2. Product Portfolio
15.3.3.3. SWOT Analysis
15.3.3.4. Financial Overview
15.3.3.5. Strategic Overview
15.3.4. Octapharma AG
15.3.4.1. Company Overview
15.3.4.2. Product Portfolio
15.3.4.3. SWOT Analysis
15.3.4.4. Financial Overview
15.3.4.5. Strategic Overview
15.3.5. Nihon Pharmaceutical Co.,Ltd
15.3.5.1. Company Overview
15.3.5.2. Product Portfolio
15.3.5.3. SWOT Analysis
15.3.5.4. Financial Overview
15.3.5.5. Strategic Overview
15.3.6. Akari Therapeutics, PLC
15.3.6.1. Company Overview
15.3.6.2. Product Portfolio
15.3.6.3. SWOT Analysis
15.3.6.4. Financial Overview
15.3.6.5. Strategic Overview
15.3.7. China Biological Products Holdings,Inc.
15.3.7.1. Company Overview
15.3.7.2. Product Portfolio
15.3.7.3. SWOT Analysis
15.3.7.4. Financial Overview
15.3.7.5. Strategic Overview
15.3.8. Biotest AG
15.3.8.1. Company Overview
15.3.8.2. Product Portfolio
15.3.8.3. SWOT Analysis
15.3.8.4. Financial Overview
15.3.8.5. Strategic Overview
15.3.9. Kedrion S.p.A
15.3.9.1. Company Overview
15.3.9.2. Product Portfolio
15.3.9.3. SWOT Analysis
15.3.9.4. Financial Overview
15.3.9.5. Strategic Overview
❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer
